Month: June 2020

Top federal health officials told lawmakers Tuesday the U.S. needs a more unified national response and funding for public health funding if the country faces another pandemic.  The U.S. is now reporting nearly 40,000 new coronavirus cases every day — almost double from about 22,800 in mid-May — driven largely by outbreaks in a number of states
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising treatment for COVID-19, a randomized, open-label trial suggests. In the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19), investigators randomly assigned 105
FDA Approves Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for HER2-Positive Breast Cancer Print this page South San Francisco, CA — June 29, 2020 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta® (pertuzumab)
In patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), nearly 30% responded to treatment with the selective inhibitor of nuclear export selinexor (Xpovio), a single-arm phase IIb trial showed. In SADAL, 28% of the 127 patients with two to five lines of prior therapy responded to the twice-weekly 60-mg dose of the drug
Our group of college friends planned to attend alumni weekend in June. But cancer and COVID changed our plans. Through a series of messages, and phone calls, we heard the news: it is cancer. The cancer diagnosis and treatment planning all happened during COVID. We still wanted to celebrate our friendship, so we planned our
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. A new review outlines a three-stage classification of the impact of COVID-19 on the central nervous system and recommends hospitalized patients with the virus all undergo MRI to flag potential neurologic damage and inform postdischarge monitoring. In stage 1, viral damage
Print this page NORTH CHICAGO, Ill., June 26, 2020 /PRNewswire/ – Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License
casimersen Treatment for Duchenne Muscular Dystrophy Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45 Print this page CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today
Print this page CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 19, 2020 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a 300 mg single-dose pre-filled pen for Dupixent® (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma and chronic rhinosinusitis with
In a three-part “Clinical Challenges” series, MedPage Today addressed several aspects of ovarian cancer: the use of so-called PARP inhibitors; repeat cytoreductive surgery following recurrence; and management of platinum-resistant disease. Test your knowledge on one aspect of each of these topics with this three-question quiz. Correct answers and explanations will appear after completing the quiz.
With government support, three coronavirus vaccines are expected to be studied in large-scale clinical trials in the next three months. “The best we’ve ever done is measles, which is 97 to 98 percent effective,” said Fauci, the director of the National Institute of Allergy and Infectious Diseases. “That would be wonderful if we get there.